Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup in Patients Suffering a Upper Respiratory Tract Infection (URTI)

PHASE3CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Upper Respiratory Infections
Interventions
DRUG

IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin

Single dose syrup containing a warming flavor IFF flavor 316 282, in a syrup containing Paracetamol 500 mg + phenylephrine 10mg + Guaifenesin 200 mg per 30 ml syrup

Trial Locations (1)

H3P3P1

Algorithme Pharma, Montreal

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Consumer Health

UNKNOWN

lead

Novartis

INDUSTRY